Literature DB >> 23929926

Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?

Sankar D Navaneethan1, Emmanuel L Bravo.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23929926      PMCID： PMC3789348          DOI： 10.2215/CJN.07370713

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  21 in total

1.  Effects of dietary sodium and potassium intake and acute stimulation on aldosterone output by isolated human adrenal cells.

Authors:  G H Williams; L M Braley
Journal:  J Clin Endocrinol Metab       Date:  1977-07       Impact factor: 5.958

2.  Role of aldosterone in the remnant kidney model in the rat.

Authors:  E L Greene; S Kren; T H Hostetter
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

3.  Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

Authors:  K J Schjoedt; K Rossing; T R Juhl; F Boomsma; L Tarnow; P Rossing; H-H Parving
Journal:  Kidney Int       Date:  2006-06-14       Impact factor: 10.612

4.  Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.

Authors:  Kohzo Nagata; Koji Obata; Jinglan Xu; Sahoko Ichihara; Akiko Noda; Hirotaka Kimata; Tomoko Kato; Hideo Izawa; Toyoaki Murohara; Mitsuhiro Yokota
Journal:  Hypertension       Date:  2006-02-27       Impact factor: 10.190

5.  Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.

Authors:  Sang-Youb Han; Cy-Hyun Kim; Han-Seong Kim; Yi-Hwa Jee; Hye-Kyoung Song; Mi-Hwa Lee; Kum-Hyun Han; Hyoung-Kyu Kim; Young-Sun Kang; Jee-Young Han; Young-Sik Kim; Dae-Ryong Cha
Journal:  J Am Soc Nephrol       Date:  2006-03-29       Impact factor: 10.121

6.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

7.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

8.  Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

Authors:  K J Schjoedt; S Andersen; P Rossing; L Tarnow; H-H Parving
Journal:  Diabetologia       Date:  2004-11-17       Impact factor: 10.122

9.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

10.  Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice.

Authors:  Anne Garnier; Jennifer K Bendall; Sebastien Fuchs; Brigitte Escoubet; Francesca Rochais; Jacqueline Hoerter; Johnny Nehme; Marie-Lory Ambroisine; Noeleen De Angelis; Gilles Morineau; Pauline d'Estienne; Rodolphe Fischmeister; Christophe Heymes; Florence Pinet; Claude Delcayre
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690
View more
  3 in total

1.  miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes.

Authors:  Renzhi Hu; Xuan Li; Chuan Peng; Ruifei Gao; Linqiang Ma; Jinbo Hu; Ting Luo; Hua Qing; Yue Wang; Qian Ge; Zhihong Wang; Chaodong Wu; Xiaoqiu Xiao; Jun Yang; Morag J Young; Qifu Li; Shumin Yang
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07

2.  Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.

Authors:  Xiaotong Song; Yue Zhao; Shijun Wang; Yuan Wang; Qian Chen; Haijun Zhao; Hua Wang; Sheng Tian; Huayun Yu; Zhichun Wu
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

3.  Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients.

Authors:  Takuro Abe; Kentaro Jujo; Motoko Kametani; Yuichiro Minami; Noritoshi Fukushima; Katsumi Saito; Nobuhisa Hagiwara
Journal:  ESC Heart Fail       Date:  2020-08-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.